Article info
PDFReview
Nodal and paranodal antibody-associated neuropathies
- Correspondence to Dr Janev Fehmi, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK; janev.fehmi{at}ndcn.ox.ac.uk
Citation
Nodal and paranodal antibody-associated neuropathies
Publication history
- Accepted April 5, 2021
- First published May 26, 2021.
Online issue publication
January 10, 2022
Article Versions
- Previous version (9 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Nodes, paranodes and neuropathies
- Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies
- IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality
- Treatment of CIDP
- Multifocal motor neuropathy: controversies and priorities
- Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment
- Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype
- Chronic inflammatory demyelinating polyneuropathy: a rare cause of falls
- Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy
- Iatrogenic immune-mediated neuropathies: diagnostic, epidemiological and mechanistic uncertainties for causality and implications for clinical practice